• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent

May 13, 2022 By Sean Whooley

Medtronic logo updatedMedtronic (NYSE:MDT) announced today that it received FDA approval for its Onyx Frontier drug-eluting stent (DES).

Onyx Frontier, the latest iteration of Medtronic’s Resolute DES family, was designed to leverage the same stent platform as Resolute with an enhanced delivery system for improving deliverability and increasing acute performance, even in the most challenging of cases.

The stent was designed to treat patients with coronary artery disease (CAD), according to a news release. A physician delivers the stent through a minimally invasive procedure to prop open the artery to treat a blockage of heart arteries.

Onyx Frontier features increased catheter flexibility, an innovative dual-layer balloon technology and a lower crossing profile. It offers a broad size matrix to treat more patients, with Medtronic saying it is the only 2 mm DES available in the U.S. It also comes in 4.5-5 mm sizes that can be expanded to 6 mm to support extra-large vessels.

The platform shares the same clinical indications as the Resolute Onyx, including for patients at high risk of bleeding who may benefit from a dual antiplatelet therapy (DAPT) duration as short as one month.

Medtronic said the now FDA-approved Onyx Frontier is currently pending CE mark approval.

“The Onyx Frontier DES FDA approval is a very important milestone for Medtronic’s coronary business and demonstrates our commitment to interventional cardiologists by providing best-in-class products,” Medtronic SVP and President of its Coronary and Renal Denervation business Jason Weidman said in the release. “The Onyx Frontier launch also correlates directly to Medtronic’s commitment to engineering. The team built upon the design and clinical successes of the Resolute Onyx DES and has continued to evolve proven DES technology to further address the needs of physicians. We look forward to continuing the pursuit of innovation each day.”

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Vascular Tagged With: FDA, Medtronic

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS